The anti-neprilysin market is an emerging therapeutic area for cardiovascular diseases. Neprilysin inhibitors work by degrading endogenous vasoactive peptides that are involved in cardiovascular functions. The approval of the first-in-class drug Entresto for heart failure treatment opened up opportunities for other players to enter this space. The anti-neprilysin drugs offer an alternative...